BioSpace News Archive

Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced that the Company will participate in H.C. Wainwright 23rd Annual Global Investment Conference.

Thyme Care, an oncology care management solution providing high touch, tech-enabled cancer care navigation, today announced a partnership with Clover Health, (Nasdaq: CLOV) (“Clover”), a technology company committed to improving health equity for America’s underserved seniors.

Statera BioPharma, a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, provided an update on the integration of the ImQuest BioSciences business unit and the status of the post-merger stock conversion process.

CPC, part of Dover and maker of a broad range of single-use connectors, announced the launch of a new ultra-compact sterile connector providing biopharmaceutical manufacturers a much-needed alternative to tube welding for their small-volume closed aseptic processes.

TMR Research has rich experience in developing state-of-the-art reports for a wide array of markets and sectors.

The reports at TMR Research provide qualitative solutions that break the barriers of doubt or uncertainties when the stakeholders plan to expand their growth reach.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per the insights by Fact.MR, the global market for transesophageal echocardiography is projected to grow at a steady CAGR over the assessment period 2021-2031.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global capnography market is set to witness steady growth between 2021 and 2031.

Astellas Pharma Inc. announced that it has voluntarily paused screening and dosing of additional participants in its ASPIRO clinical trial evaluating AT132 in patients with X-linked Myotubular Myopathy.

MedinCell and Teva announced yesterday the FDA acceptance of the New Drug Application for mdc-IRM for patients with schizophrenia.